Southeast Michigan

PHASIQ’s proprietary Micropatterned Phase-Separation Technology™ enables scientists to measure protein levels in a multiplex, cost-effective and cross-reaction free manner, thereby accelerating protein diagnostics and therapeutics development. PHASIQ has exclusive worldwide licenses to three US and PCT patents and pending patents for our core technology from the University of Michigan. PHASIQ is developing research-use-only multiplex ELISA protein immunoassay kits for targeted conditions within immune disorders, cardiovascular diseases, and cancer.